semaglutide opportunities does .25 mg of work For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management Switching from Semaglutide to Tirzepatide:

While the increase in risk appears modest, the findings raise important questions about how rapid weight loss and appetite suppression may affect bone health over time

Corrias S, Fosci M, Galletta M, Boi F, Baghino G, Oppo A et al (2024) Mediterranean Diet adherence, physical activity level, and quality of life in patients affected by thyroid diseases: Comparison between pre- and post-lockdown assessment

People with obesity [experience] many conditions including increased risk of cardiovascular disease, stroke, arrhythmias, sleep apnea, and even cancers

Four cancers showed statistically significant reductions: non-small cell lung cancer, breast cancer, colorectal cancer and liver cancer